Skip to content

Molecular Genetic Study of Mayer-Rokitansky-Kuster-Hauser Syndrome

Etude de Génétique moléculaire du Syndrome de Mayer-Rokitansky-Kuster-Hauser

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02967822
Acronym
MRKH
Enrollment
410
Registered
2016-11-18
Start date
2016-05-31
Completion date
2031-05-31
Last updated
2018-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mayer Rokitansky Kuster Hauser Syndrome

Brief summary

In order to understand the molecular mechanisms leading to Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH), the research team has to identify molecular bases of this anomaly. Toward this goal, the research team would like to include in the study patients with MRKH syndrome, as well as their healthy relatives, in order to perform genetic analyses, especially whole exome sequencing. This study has been set up in order to collect biological samples from patients with MRKH and their relatives.

Detailed description

The MRKH is a congenital and rare malformation characterised by the absence of the uterus and of 2/3 of the vagina. The incidence is 1 in 4500 female children (46,XX) and a genetic component has been identified. In order to understand the molecular mechanisms leading to this disease, the research team has to identify the genetic abnormalities. This study will be led by the research team of the Imagine Institute and the clinical teams associated with the Reference Center for Rare Diseases PGR (Rare Gynecologic Diseases). Both groups are based on the Necker Hospital campus, and already closely collaborate on research into MRKH syndrome. This collaboration will allow to : i) collect biological samples from the propositus and their relatives, ii) have a medical expertise. The clinicians involved in the study will recruit patients, whose participation will involve providing a biological sample, ie, a blood sample and/or uterine tissue collected during surgical ablation, in the event that surgery is performed during clinical follow-up of the patients. No specific intervention will be planned for the purposes of this study. In order to perform genetic analysis on trios, the healthy relatives of the patients (parents, brothers, sisters) will also be included. Blood samples will be taken once for healthy relatives. Genetic analysis, especially whole exome sequencing, will be performed on blood samples by the research team of Imagine Institute.

Interventions

GENETICBiological samples for patients

Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)

GENETICBiological samples for healthy relatives

Blood samples.

Sponsors

Reference center for rare diseases (Rare Gynecologic Diseases)
CollaboratorUNKNOWN
Imagine Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patient with MRKH syndrome OR healthy relative of patient included * Having signed the Informed consent form (or parents in case of patient under 18 years)

Exclusion criteria

* Refusal to participate in genetic analyses * Participation in a therapeutical clinical study in the 30 days prior to inclusion in the present study.

Design outcomes

Primary

MeasureTime frameDescription
Number of identified nucleotidic variation(s) whose consequences can explain the phenotype of MRKH syndrome15 yearsGenetic cause identification

Countries

France

Contacts

Primary ContactStanislas Lyonnet
stanislas.lyonnet@inserm.fr+33 1 44 49 51 36
Backup ContactAnna Pelet
anna.pelet@inserm.fr+33 1 42 75 43 08

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026